Skip to main content

Dutch antitrust regulators are looking into claims that Biogen may have used its strong market position unfairly in the area of MS treatments and related blood tests, according to STAT. The investigation focuses on whether Biogen's conduct restricted competition.

This move signals increased regulatory scrutiny for large pharma companies, especially those with a significant share in specialised treatment markets. Senior executives should assess their own practices for compliance and anticipate possible regulatory changes or enforcement actions.

STAT reports that incoming Democratic chairs of major committees are preparing to investigate most-favoured-nation (MFN) drug pricing agreements made between drugmakers and the Trump administration. The move signals possible scrutiny of past pricing policies and their impact on the pharmaceutical sector.

This development matters for pharma executives and healthcare leaders as it may lead to regulatory reviews or changes in how drug prices are set in the US. Companies could face new compliance demands or shifts in reimbursement models if the investigation gains traction.

Oura, known for its wearable smart rings, will acquire Counsel Health, a clinical AI startup, for $625 million, according to STAT. The move comes as Oura postponed its public listing and seeks to broaden its reach in healthcare technology.

For regulated-industry leaders, this deal points to growing interest in AI solutions within digital health. It may prompt competitors and incumbents to assess their own AI strategies and partnerships. The acquisition could also influence how health data is used in clinical and consumer settings.

The FDA has issued a warning that GLP-1 drugs, used for obesity and diabetes, may increase the risk of a rare but serious eye condition sometimes called an "eye stroke," according to STAT.

This warning raises regulatory and safety concerns for pharmaceutical companies involved in the development and marketing of GLP-1 drugs. Leaders in the sector may need to assess current safety data and consider adjustments to product labelling, as well as prepare for possible changes in prescribing practices.

STAT reports that the Trump administration has taken WuXi AppTec off its list of Chinese military companies operating in the US. WuXi AppTec is an important partner for many pharmaceutical companies.

This change reduces some regulatory and geopolitical risk for pharma firms that rely on WuXi for research or manufacturing. However, companies should remain alert for further changes in US policy that could affect global supply chains or cross-border partnerships.

STAT reports that Bayer has received FDA approval for a new drug, the first in a novel class intended to prevent blood clots without raising the risk of bleeding. The drug targets patients at risk of stroke recurrence and is positioned as a safer alternative to current therapies.

This approval may influence treatment protocols in stroke prevention and could affect market competition among pharmaceutical companies. Healthcare leaders should monitor how quickly the drug is adopted and whether insurers will cover it, as this will shape access and commercial impact.

STAT reports that a much-anticipated AI technology designed to accelerate drug discovery has not met expectations. The article points to another instance where the promise of AI-led breakthroughs in heart drug development did not materialise.

This outcome matters for pharma and biotech leaders who face growing pressure to adopt new technologies while managing risk and regulatory scrutiny. The case serves as a reminder to scrutinise AI claims and ensure robust validation before committing resources or altering research strategies.

AI-driven drug research disappoints again in pharma sector

According to STAT, Novartis presented data at the AHA conference showing its drug reduced a key risk marker for cardiovascular disease but did not decrease the actual risk of heart attack or stroke. The result raises new questions about the link between biomarkers and clinical outcomes.

This matters for pharma and biotech executives as it challenges the value of targeting certain biomarkers in drug development. Companies may need to reassess their clinical trial endpoints and consider broader measures of patient benefit.

Novartis drug lowers risk marker but fails to cut heart attack rates

STAT reports that the Biotechnology Innovation Organization (BIO) has joined a legal challenge against a US Medicare pilot programme that links drug prices to those in peer countries. The model is described as a test of the Trump administration's most-favoured nation approach to drug pricing, but its impact is expected to be limited, according to STAT.

This legal action signals resistance from the biotech sector to government efforts to control drug costs by referencing international prices. For pharma and biotech executives, the outcome could shape future US pricing models and influence global pricing strategies.

BIO challenges US Medicare pilot linking drug prices to peer nations

STAT reports that Democrats are likely to prioritise reversing Medicaid cuts and expanding insurance coverage, which could benefit healthcare providers. The party’s midterm gains may lead to changes in funding and access for hospitals, according to the source.

For hospital executives and healthcare leaders, this signals possible relief from recent funding pressures. Any regulatory changes could affect reimbursement models and patient volumes. Monitoring legislative developments will be key for operational planning.

Democrats’ midterm gains may ease pressure on US hospitals